Last reviewed · How we verify
Ascentage Pharma HQP1351 bioavailable inhibitor
Ascentage Pharma HQP1351 bioavailable inhibitor is a Small molecule drug developed by Ascentage Pharma Group Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Ascentage Pharma HQP1351 bioavailable inhibitor |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ascentage Pharma HQP1351 bioavailable inhibitor CI brief — competitive landscape report
- Ascentage Pharma HQP1351 bioavailable inhibitor updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI
Frequently asked questions about Ascentage Pharma HQP1351 bioavailable inhibitor
What is Ascentage Pharma HQP1351 bioavailable inhibitor?
Ascentage Pharma HQP1351 bioavailable inhibitor is a Small molecule drug developed by Ascentage Pharma Group Inc..
Who makes Ascentage Pharma HQP1351 bioavailable inhibitor?
Ascentage Pharma HQP1351 bioavailable inhibitor is developed by Ascentage Pharma Group Inc. (see full Ascentage Pharma Group Inc. pipeline at /company/ascentage-pharma-group-inc).
What development phase is Ascentage Pharma HQP1351 bioavailable inhibitor in?
Ascentage Pharma HQP1351 bioavailable inhibitor is in Phase 1.